Russia expects India to approve Sputnik V vaccine for use soon - report

By Krishna N. Das NEW DELHI (Reuters) - India is expected to grant emergency use authorization for Russia's Sputnik V COVID-19 vaccine this month or next, the Russian Direct Investment Fund (RDIF), which markets the shot abroad, told Indian news agency ANI on Tuesday. India has already approved two other vaccines for emergency use and has inoculated nearly 4 million people since mid-January in what the government touts as the world’s biggest immunization campaign, aiming to vaccinate over 300 million people by August.

Reuters February 03, 2021 00:11:47 IST
Russia expects India to approve Sputnik V vaccine for use soon - report

Russia expects India to approve Sputnik V vaccine for use soon  report

By Krishna N. Das

NEW DELHI (Reuters) - India is expected to grant emergency use authorization for Russia's Sputnik V COVID-19 vaccine this month or next, the Russian Direct Investment Fund (RDIF), which markets the shot abroad, told Indian news agency ANI on Tuesday.

India has already approved two other vaccines for emergency use and has inoculated nearly 4 million people since mid-January in what the government touts as the world’s biggest immunization campaign, aiming to vaccinate over 300 million people by August.

"India is a key partner in terms of production of vaccine and we expect that there'll be a restricted emergency use order for the Sputnik V vaccine...this month or next. After that we will be able to start our vaccine delivery to India," RDIF chief Kirill Dmitriev was quoted by ANI as saying.

RDIF is likely to apply for Indian authorization this month, said a source with direct knowledge of the matter who asked not to be identified as he is not authorized to talk to the media.

The Sputnik V vaccine was given a green light on Tuesday by scientists in Russia after its scientists said it was found to be 92% effective based on peer-reviewed late-stage trial results.

In January an independent board in India found the Sputnik V shot to be safe in a mid-stage trial. RDIF said the late-stage clinical trials also showed strong efficacy and safety.

India has recorded 10.8 million COVID-19 infections and over 154,000 deaths from the pandemic - the world's second and third highest tolls respectively. But the true infection figure may be dramatically higher based on a new survey indicating that more than half of New Delhi's 20 million people may have been infected with the coronavirus .

India is the world's largest vaccine maker and a Russian official said in December that it was likely to be able to produce 300 million doses or more of Sputnik V vaccine in 2021.

India's Hetero Biopharma has already announced a deal with the RDIF to make more than 100 million doses of Sputnik V and Indian drugmaker Dr. Reddy's, which has conducted clinical trials, will help in distributing the vaccine..

On Tuesday, India reported 8,635 new cases of COVID-19 which is the lowest since June 2, 2020.

(Reporting by Krishna N. Das, Writing by Nupur Anand; Editing by Mark Heinrich)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Robinhood now a go-to for young investors and short sellers
Business

Robinhood now a go-to for young investors and short sellers

By John McCrank NEW YORK (Reuters) - Robinhood, the online brokerage used by many retail traders to pile in to heavily shorted stocks like GameStop Corp, has made an ambitious push into loaning out its clients' shares to short sellers as it expands its business. The broker had $1.9 billion in shares loaned out as of Dec. 31, nearly three times the $674 million a year earlier, and it was permitted to lend out $4.6 billion worth of securities under margin agreements, around five times bigger than the prior year, according to an annual regulatory filing late on Monday

Wall Street mixed as Apple and Tesla retreat
Business

Wall Street mixed as Apple and Tesla retreat

By Noel Randewich (Reuters) - Wall Street was mixed on Tuesday, with Apple and Tesla losing ground, while materials and energy companies climbed as investors looked toward the U.S. Congress approving another stimulus package.

Biden's SEC nominee vows review of GameStop trading issues, climate disclosures
Business

Biden's SEC nominee vows review of GameStop trading issues, climate disclosures

By Pete Schroeder and Chris Prentice WASHINGTON (Reuters) - U.S. President Joe Biden's pick to head a key market regulator promised on Tuesday a thorough review of issues raised by the GameStop Corp stock frenzy and suggested companies may have to disclose their potential risks from climate change